Show results for
Refine by
Vaccine S Storage During Its Develop Equipment Supplied In Sweden
6 equipment items found
Manufactured by:2A Pharma ApS based inAalborg Øst, DENMARK
Head and neck cancers represent the sixth most common cancer worldwide, resulting in more than 350,000 deaths/year. Our AAVLP-HNC vaccine uses our mimotope selection technology and has the potential to minimize side effects, improve efficacy, and markedly reduce treatment costs. This will address an unmet medical need and benefit cancer patients as well as reduce healthcare expenses. In addition, ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Novavax' saponin-based Matrix-M improves immune responses and enables vaccine dose-sparing. Matrix-M adjuvant is a valuable component of vaccine development, providing multiple immune system enhancements, a well-understood mechanism of action, and robust clinical experience where it was shown to be well tolerated in human studies to ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS candidate was based on the major surface spike protein, which we had previously identified as the ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
Historically, we developed a vaccine candidate against MERS, a novel coronavirus first identified in 2012, as well as a vaccine candidate against SARS in 2005. In 2012, within weeks of obtaining the sequence of the circulating MERS strain, we successfully produced a vaccine candidate. Our MERS candidate was based on the major surface spike protein, which we had previously identified as the ...
Manufactured by:Novavax based inGaithersburg, MARYLAND (USA)
We have developed an EBOV glycoprotein vaccine candidate (Ebola GP vaccine) expressed in insect cells, using our core recombinant baculovirus technology. In 5 separate studies, carried out in collaboration with the National Institute of Allergy and Infectious Diseases, active immunization with the Ebola GP vaccine was shown to be highly immunogenic and efficacious in preventing lethal disease in ...
Manufactured by:Abera Bioscience AB based inUppsala, SWEDEN
Abera’s proprietary vaccine delivery platform – BERA, enables high-level multivalent presentation of recombinant antigens on bacterial Outer Membrane Vesicles (OMVs) for strong stimulation of the immune ...